CHO Cell Lines usually adopt the fed-batch process as a primary methods to manufacturing recombinant protein therapeutics. 

Process development for this method has been usually on how best to support high-cell density cultures that are necessary to achieve high product titres production. The issue however has always been the high nutritional demands required. If there is a lack of key nutrients, cell growth will be affected and with it, the inability to produce these proteins. 

In this white paper, Bayer Healthcare discussed about its partnership with Life Technologies (now Thermo Fisher Scientific) and implementation a novel, propriety nutrient addictive GIBCO FunctionMAX Titer Enhancer, and combined it with several other feeds to enhance CHO Cell Culture performance. 

Cell Culture is a key component at the BioPharma Asia Convention 2015. With Asia's biopharma moving even faster into manufacturing, delegates are now becoming more curious on adopted approaches and weighing the possibilities of using them for themselves. 

Check out the BioPharma Asia Convention website at www.terrapinn.com/exhibition/bio-asia to learn how you can join us in our 24-25 March gathering of Asia's Biopharma industry!